Technologies

CycloSam^® Sm-153 DOTMP Spun-Out into IGL Pharma, Inc.

A new company, IGL Pharma, Inc. has been formed to move CycloSam^® forward through clinical trials. CycloSam^® is a patented new bone-seeking radiopharmaceutical being developed for bone cancers, including the treatment of primary bone tumors, secondary bone metastases and for bone marrow ablation/transplant.

BetaBrach™ – Brachytherapy Treatment for Solid Tumors

IsoTherapeutics, in collaboration with the Gabriel Institute and Valco Instruments Company, Inc. has developed a novel patented method to treat solid inoperable tumors. Traditional brachytherapy uses encapsulated gamma emitters which makes irradiation of non-target tissue a potential issue. Beta emitters, which would have a much smaller field of irradiation, are generally not used in this manner because the capsules would effectively shield the beta particles. Use of beta emitters without encapsulation would normally result in the migration of isotope and thus radiation dose to non-target tissues. BetaBrach™ involves a simple and effective chemical approach to immobilizing metallic radioisotopes. This technology is available for license.

Testimonials

A small company with high caliber people. This company helped me address critical questions posed by the FDA.

Ebrahim S. Delpassand, M.D.
Chairman & Medical Director Excel Diagnostics

IsoTherapeutics has proven to be a partner able to adapt quickly to FUJIFILM's changing needs. Within two weeks, they had documentation in place for the preparation of two new blood testing kits, and prepared GMP batches of each for our clinical sites.

Takeaki Suzuki, Ph.D.
Associate Director, Drug Development, Head of Operations, FUJIFILM Pharmaceuticals USA, Inc.

The combination of R&D, cGMP and small animal testing facilities makes IsoTherapeutics the ideal partner for our radiopharmaceutical programs - from initial development to commercialization. The skills that IsoTherapeutics have brought to our product development programs over the past decade have proven to be a major contribution to our success.

Nigel R. Stevenson, Ph.D.
COO, Serene, LLC

Technologies

Testimonials

Contact Us